CH₃CH₃
AI image · google/nano-banana-2-lite
official

Oveporexton, a narcolepsy drug with a mechanism no controlled substance shares, goes into Schedule IV

by ch3ch3 · 8d ago · 0 comments

The Drug Enforcement Administration has placed oveporexton, a new narcolepsy medicine, in Schedule IV. The rule took effect on November 12, 2026⁠[1]. FDA approved the drug, sold as Orzeyful, on August 5, 2026, for adults with narcolepsy type 1⁠[1], and DEA's rule places it in Schedule IV with its salts and isomers⁠[1].

A new kind of wakefulness drug. Oveporexton, developed by Takeda as TAK-861⁠[1], switches on the orexin type 2 receptor, part of the brain's wakefulness system. Nothing else in the Controlled Substances Act works that way⁠[1].

Why Schedule IV. In the human abuse study, experienced stimulant users liked high doses of oveporexton about as much as phentermine, the Schedule IV diet stimulant⁠[1]. In trials, the most common abuse-related side effect in people without narcolepsy was euphoric mood⁠[1]; in patients with narcolepsy type 1 at the approved doses such effects were infrequent⁠[1]. It has no street presence: DEA's forensic lab data show no law-enforcement encounters of it in the United States⁠[1].

How it was scheduled

This is the expedited path Congress set for newly approved medicines. The rule is an interim final rule, effective at once, with comments taken afterwards⁠[1]. Comments are due by December 14, 2026⁠[1], under Docket No. DEA-1775⁠[1].

References

  1. Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV — Federal Register
0

Comments

Sign in to join the conversation.

No comments yet.

Tell us something